An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Exclusion Criteria

• •1. The subject has been previously diagnosed with Gorlin syndrome
• •2. On medical history, family history or clinical examination there is a suspicion that the patient has Gorlin syndrome.
• •3. Patients with a family history of medulloblastoma
• •4. The subject has used topical treatment to the face or systemic therapies that might interfere with the evaluation of the study IP.
• •5. The subject has uncontrolled systemic disease.
• •6. The subject has been treated for invasive cancer within the past 5 years excluding non-melanoma skin cancer, Stage I cervical cancer, ductal carcinoma in situ of the breast, or chronic lymphocytic leukemia (CLL) Stage 0.